Trial Profile
A Randomized Multi-Center Treatment Study (COALL 08-09) to Improve the Survival of Children With Acute Lymphoblastic Leukemia on Behalf of the German Society of Pediatric Hematology and Oncology
Status:
Active, no longer recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Clofarabine (Primary) ; Amsacrine; Cyclophosphamide; Cytarabine; Daunorubicin; Dexamethasone; Doxorubicin; Etoposide phosphate; Mercaptopurine; Methotrexate; Methotrexate; Methotrexate; Methylprednisolone; Pegaspargase; Prednisone; Tioguanine; Vincristine
- Indications Precursor B-cell lymphoblastic leukaemia-lymphoma; Precursor T-cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; Therapeutic Use
- 08 Dec 2020 Results presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology
- 29 Mar 2020 Status changed from recruiting to active, no longer recruiting.
- 06 Oct 2019 Planned End Date changed from 1 Sep 2016 to 1 Dec 2024.